Compass Therapeutics registers Phase 2 study of CTX-471 in NCAM-positive neuroendocrine tumors
The trial will test CTX-471 at two dose levels in patients with metastatic neuroendocrine neoplasms that have progressed after standard treatment.
Compass Therapeutics has a newly listed Phase 2 study for its drug CTX-471.
- CTX-471 is being developed for patients with central lab confirmed NCAM (CD56 IHC) positive metastatic neuroendocrine neoplasms that have progressed after standard of care treatment1. The study, registered as NCT07684170, is status not yet recruiting1 with an estimated start of 2026-09. The drug will be administered as an intravenous (IV) infusion at either 0.3 mg/kg or 0.6 mg/kg every 2 weeks until disease progression or unacceptable toxicity1. The study plans to enroll 18 patients per dose level in Stage 1, with an additional 22 patients in Stage 2 if enough responses are seen1, for an estimated total enrollment of 58 participants. The primary outcome is clinical activity measured by Objective Response Rate per RECIST Version 1.11.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.